Life Sciences Archive » October, 2016

Life Sciences - October, 2016

330 articles

• 2nd Circ. Urged Not To Revisit Pregnancy Test False-Ad Suit
• Judge Adds $21M To CardiAQ's $70M Trade Secrets Win
• Pfizer, Others Tell High Court PTAB Unfair To Patent Owners
• FDA Recommends Boxed Warning On Essure, Similar Devices
• Endo Says FTC Needs Permission To Pull Pay-For-Delay Suit
• U Of California Sues Boston Scientific Over AFib Devices
• Third Rock Closes Fourth Biotech Venture Fund At $616M
• SEC Says PwC Auditor Should Have Caught Fund Fraud
• EcoMed's $22M Contract Suit Sent To Mediation
• Stryker Can't Escape Hip Replacement Suit
• Prior Defects Could Sink Auvi-Q Even As EpiPen Prices Soar
• NJ Atty Urges 3rd Circ. To Rethink Frivolity Sanctions
• Justices Won't Hear Chemical Co.'s Infringement Appeal
• Generic Drug Co. Can't Kill Merck IP Suit Over Antifungal
• US Looks To Reinstate Charges In Meningitis Outbreak Suit
• 3rd Circ. Won't Rethink Provigil Antitrust Decision
• Adapt Or Die: Law Firms In Tomorrow's Economy — Part 2
• 3rd Circ. Weighs In On Product-Hopping
• When Your Client Is The President: Part 7
• Trial Bundling Comes Under Fire In Boston Scientific Appeal
• FDA OKs St. Jude Device For Lowering Certain Stroke Risks
• Is Talc The New Tobacco? $200M J&J Verdicts Show Potential
• PTAB Wins For Bass May Not Move Needle On Drug Prices
• Calif. Appeals Court Chops $13M Cooling Device Verdict
• FCA Decision Tracker: How Escobar Is Being Interpreted
• Promega Urges Justices To Back IP Meaning Of 'Substantial'
• CVS Settles Wage Statement Suit For $3M
• Don't 'Friend' Potential Jurors, IP Row Judge Warns Attys
• GSK Tells 3rd Circ. To End La. Case Over Settled Claims
• Misjoinder And Forum Shopping By The Government
• Judge Limits Zimmer Subpoenas To 'Shadow Organization'
• Unity Biotechnology Rakes In $116M From Investors
• Colgate, Tom's Face Suit Over 'Natural' Product Claims
• Astellas To Pay Up To $1.4B For German Cancer Drug Maker
• What Amici Say In High Court Patent Laches Case
• When Your Client Is The President: Part 6
• Adapt Or Die: Law Firms In Tomorrow's Economy — Part 1
• Rainmaker Q&A: Michael Best's Lisa Mueller
• Adderall Buyers Deride Objections To $15M Settlement
• J&J, Talc Co. Hit With $70M Baby Powder Cancer Verdict
• Challenge To Test Strip Injunction Falls Flat In 2nd Circ.
• Ex-Warner Chilcott Rep Gets Probation For HIPAA Violation
• Shkreli Wants To Bolster Defense With Katten Documents
• Endo Seeks Ruling On FTC Ability To Sue Over Past Conduct
• Kyle Bass Gets More Wins As PTAB Axes Celgene Patents
• GNC Tries To Throw Out 'Slack Fill' Protein Containers Suit
• University Of California Hits St. Jude With IP Suit
• Novartis, Amneal Settle Exelon Patch Infringement Fight
• Propel Orthodontics Ordered To Stop False Advertisements
• Antibody And Epitope Patent Prosecution Tips: Part 2
• When Your Client Is The President: Part 5
• Energy Drink Ad Claim Ruling Shows State Laws Matter
• China's New Social Credit System Presents Complications
• Labaton Secures $23.8M In Fees For Amgen Securities Deal
• USDA Scientist Cops To Lying About Seed-Stealing Plot
• Fed. Circ. Won't Lift Early Sales Ban In Qiagen Patent Case
• Generics Group Urges Justices To Hear Patent Locale Dispute
• Bowel Drug False Ad Suit Kept Alive
• Chicago Says Drug Cos.' Opioids Forced Spending On Addicts
• Neovasc Seeks Quick Win In Suit Over $70M Trial Loss
• Supplement Co. Says Foe Stealthily Selling Harmful Products
• 9th Circ. Revives Shareholder Suit Over Arena's Diet Drug
• VC-Backed Ra Pharmaceuticals Raises $92M In Upsized IPO
• Rainmaker Q&A: Orrick's Christina Guerola Sarchio
• Ex-Sanofi EpiPen Alternative Auvi-Q Coming Back In 2017
• Jury Hits Abbott Unit With $4.25M Age-Bias Verdict
• Bayer CEO Calls $66B Monsanto Tie-Up 'A Perfect Fit'
• Ex-Access CEO Must Repay $1.5M Kickbacks, 2nd Circ. Says
• Robbins Geller Made Lead Counsel In Insmed Stock Drop Suit
• FDA Moves Toward Online Database For Medical Device Info
• Antibody And Epitope Patent Prosecution Tips: Part 1
• When Your Client Is The President: Part 4
• InterMune Medical Chief Takes Stand Against Ex-Director
• St. Jude, Medtronic Sued Over Heart Valve Patents
• NJ Judge Sends Medical Device Co.'s Coverage Spat To Pa.
• J&J Asks Justices To End Circuit Split On Expert Misconduct
• Proctor & Gamble Get Last Fixodent Cases Axed
• Ex-Oppenheimer Adviser Cops To Insider Trading
• FDA Warning Wire: Device Deaths, Otsuka Woes, Teva Details
• FDA Unveils Site To Report Medical Device Violations
• Medicare Fraudster Gets 63 Months After 9th Circ. Win
• Nivea Maker Says No Evidence Showing Lotion Is A Drug
• Rainmaker Q&A: Greenberg Traurig's Richard Edlin
• How Pharma Cos. Can Shape The Drug-Pricing Landscape
• When Your Client Is The President: Part 3
• Bridging The Gap Between Outside And Inside Counsel
• Fla. Medical Marijuana Measure May Boost Business For Firms
• Bio-Rad Says Ex-GC Whistleblower Testimony Privileged
• CORRECTED: Pfizer Looks To Shake Damages Expert In Trade Secrets Trial
• InterMune Director Tipped Pal On Drug OK, SEC Tells Jury
• Kyle Bass Group Gets 1st Win As PTAB Nixes Gattex Claims
• Teva's Generic Overdose Drug Application Sparks IP Suit
• Listeria Prompts FDA Partial Hold On Cancer Drug Trial
• Abbott Whistleblower Urges 5th Circ. To Revive $219M Suit
• Researchers Claim No Defamation In St. Jude Security Report
• Zimmer Gets Quick Win In 2nd Knee Implant Defect Bellwether
• Recent Decisions Clarify Reach Of IPR Petitioner Estoppel
• When Your Client Is The President: Part 2
• So You Want To Be A Partner? You Need A Mentor
• Fla. Pharmacy Owner To Settle Tricare Fraud Charges For $4M
• Health Hires: Crowell & Moring, Goodwin, Faegre
• 6 Firms To Steer 7 IPOs Totaling $2.6B Led By Blockbuster
• Canadian Justices Urged To Nix 'Promise Doctrine' In IP Row
• McDermott Gains Transactional Partner From Locke Lord
• Medical Co. Never Bought Duty To Defend, Insurer Says
• Drugmaker Takes Flanax Trademark Case To Supreme Court
• Court Shows No Love for Aphrodisiac Class Certification
• Vitamin Buyers Seek Class Cert. In 'Made In USA' Suit
• When Your Client Is The President: Part 1
• J&J Talcum Powder Users Dying Of Ovarian Cancer, Atty Says
• High Court Denies Consumers Cert. In P&G Fixodent MDL
• CVS To Pay $600,000 To Settle Controlled Substance Claims
• Judge Aghast At Iowa Brothers' Defiance In NuScience IP Row
• Judge Splits FTC's Endo Case, Scoffs At Transfer Threat
• Pot Fertilizer Co. Says Denver Weed Chain Threatened TM Suit
• GSK, Teva Urge High Court To Review Pay-For-Delay Accords
• Pipe Maker, Biotech Price IPOs Raising $439M
• Merck Tells Justices Only Public Sales Trigger On-Sale Bar
• Judge Defends Jury But Carves $2M From Mesh Verdict
• Ex-NJ Prosecutor Joins Epstein Becker's Health Group
• Fed. Circ. Says It Can't Review PTAB Decision To Ax Review
• FTC, Antitrust Org Ask 3rd Circ. To Rethink Doryx Decision
• Trial Pros' Secret To Courtroom Success
• Prosecuted For Truthful Off-Label Promotion: Part 2
• Whistleblower Drops Multimillion-Dollar Lincare FCA Suit
• Supplement Maker Sued Over Dubious HGH-Boosting Claims
• Are Your Witnesses Watered Down?
• Align Stock Losses Were Fraud, Not Bad Biz, 9th Circ. Told
• Judge Refuses To Nix Depakote Birth-Defect Suit In Ill.
• USPTO Wins Dispute Over Extension For Drug Patent
• US Says Smoking Materials Importer Owes $193K In Penalties
• Legal, Biz Groups Back Pfizer In 3rd Circ. Birth Defect Row
• Theranos' Woes May Reshape Private D&O Coverage
• Relator Pulls State Insurance Fraud Claim Against Medtronic
• Supreme Court Urged To End Laches Defense In Patent Cases
• Prosecuted For Truthful Off-Label Promotion: Part 1
• Gilead Says Ferring Win Should Extend HIV Drug Exclusivity
• Biotech IPO, Two Follow-On Offerings Top $350M
• Syngenta Says Kansas Class Can't Join Trial In GMO MDL
• Boehringer Offers EU Concessions For Sanofi Swap Deal
• Talking 'Bull': Episode 4, Callisto
• Boston Scientific Urges High Court To Nix $308M IP Verdict
• St. Jude Forms Medical Device Cybersecurity Board
• GE Cites IP Atty Breach In Barnes & Thornburg DQ Motion
• Fed. Circ. Backs Nix Of GSK Flu Inhaler Patent Application
• 2nd Circ. Pushes Back As Ex-CEO Appeals Kickback Liability
• GSK Can't Seek To Deflect Blame, Reed Smith Widow Says
• FDA Warning Wire: Teva Factory Woes, Camel Milk Claims
• 7th Circ. Backs Teva In Atty's Breast Cancer Suit
• No More Vaginal Mesh Suits, MDL Judge Says
• Abbott, St. Jude Ink $1B Deal To Shed Product Portfolio
• Legal Battle Over 100-Year-Old Drug Previews Big Price Hike
• Advil 'Slack-Fill' Claims Come Up Empty, Judge Finds
• Fera Taking Loss Over Thyroid Drug Generic To Fed. Circ.
• Sanofi Seeks Early Win, Defeat Of Class Cert. In TCPA Suit
• Ysios Capital Closes $139M Euro Biotech, Health Care Fund
• Quark, GF Securities Launch $500M Health Sciences Fund
• Bayer-Monsanto Won't Seed Or Weed The Patent Thicket
• Pfizer To Launch Biosimilar Of J&J's Top-Selling Remicade
• Mylan Sued By EpiPen Buyers Over Pricing, Marketing Tactics
• Cook Medical's 2nd Bellwether Pick OK'd In Vein Filter MDL
• FDA Places Hold On Regeneron-Teva Pain Drug Study
• MoFo Nabs WilmerHale Drug IP Partner And Ex-Gilead Atty
• Provigil Pay-For-Delay Suit Belongs In Pa., Teva Says
• Hyland's To Pay Refunds, $2.9M In Fees To End False Ad Row
• Monsanto Hit With False Ad Suit Over Roundup Concentrate
• PE-Backed Acushnet Tops 5 IPO Launches Totaling $907M
• Hyland's Resists Consumer's Bid For New False Ad Trial
• Pot Zoning Rule Needs No Enviro Review, Calif. Court Says
• Mylan's $465M EpiPen Deal With DOJ Too Lenient, Sen. Says
• 3rd Circ. Got Doryx Product-Hopping Suit Wrong, Mylan Says
• Actavis Holdco Says FTC's AndroGel Antitrust Suit Is Moot
• OPINION: 3rd-Party Litigation Funding Needs Transparency
• Another Champion For Proportionality In MDL Discovery
• Omnicare Pays $28M In Depakote Kickbacks Case
• Rainmaker Q&A: Goodwin Procter's Stuart Cable
• Feds Blast Shkreli's Ex-Atty's Bid For Conspiracy Details
• Cosmetics Co. To Pay $5.6M To End Suit Over Bungled Merger
• Pfizer Settles Long-Running Cancer Research IP Suit
• Bristol-Myers Wants High Court Review Of Calif. Jurisdiction
• 3 Firms To Lead IPOs Totaling $518M As Deals Begin To Slow
• Health Hires: Greensfelder, Cozen O'Connor, Goodwin
• Infection Risk In LivaNova's Blood Temp. Device, CDC Warns
• Pfizer Unit To Pay Feds Extra $230K For NJ Pollution
• Evidence Doesn't Back $70M Pa. Risperdal Award, J&J Says
• Fed. Circ. Affirms Gilstrap's Validation Of Endo Patents
• Maynard Cooper Opens NY Office With 3 IP Partners
• Obama Opens Door To Pharma Trade With Cuba
• Law Firm Seeks To Avoid Indemnifying For GSK Settlement
• Sex Pill Claims Too Vague To Be Misleading, Judge Rules
• Drug Plaintiffs Can't Avoid Learned Intermediaries
• GSK Wants Fraud Claims Dismissed In Zofran MDL
• Pradaxa Warnings Were Adequate, Boehringer Ingelheim Says
• Boston Scientific Wants 4 New Trials After $27M Verdict
• Supplement Cos. Seek Fees From 'Patent Troll' ThermoLife
• Fed. Circ. Backs MIT In Cell-Growing Mesh Patent Case
• NJ Time Limits Should Apply To Accutane Case, Justices Told
• Astellas Targets Generic Versions Of Bladder Drug Myrbetriq
• A Gift By Any Other Name: Benefits In McDonnell And Salman
• Escobar Supports Nixing $40B FCA Suit, Celgene Says
• Sandoz, Taro, Others Hit With Antitrust Suit Over Skin Cream
• NJ Accutane Litigation Trimmed By 160 Suits
• Life Alert To Pay $3.2M To End Workers' FLSA Suit
• Pfizer Asks 3rd Circ. To Uphold Its Win In Birth Defect MDL
• Calif. Life Sciences Cos. Sued Over Sale Of Fetal Tissue
• Allergan, Others Fight Eye Drop Class Cert. At 7th Circ.
• Theranos, Walgreen Blood-Test Suits Consolidated In Ariz.
• 5th Circ. Tells Widow Vioxx Deal Protects Seeger Weiss
• J&J Trial's Remote Witnesses Test Limits Of Subpoena Power
• Allergan Investors Urge Class Cert. In Insider Trading Row
• 10 Baby Deaths Possibly Tied To Teething Products, FDA Says
• Whistleblowers Revive Novartis Xolair Kickback Suit In NY
• Extraction Oil & Gas Tops 3 IPOs Totaling $700M
• Treasury's Inversion Rule Undermines Tax Law, Chamber Says
• Ice Cream And Talking Pictures: Brandeis On Patents
• 3rd Circ. Upholds Zimmer Win In Replacement Hip Suit
• Actavis Looks To Flip 'Pill Mill' Coverage Loss On Appeal
• Warner Chilcott Wants Claims Cut In Generic-Blocking Suit
• The Art Of Silence At Trial
• Besin Denied Quick Exit In Testosterone Replacement MDL
• Similar NY Case Moots Del. Derivative Suit, BioScrip Says
• FDA Says Faulty Device Didn't Affect Xarelto Trial Results
• Justices Won't Hear Merck Challenge Of AIA Appeal Standard
• FDA Warning Wire: Pistachios Linked To Salmonella Outbreak
• Army Accused Of Price Bamboozle In $40M Staffing Contract
• Ex-Warner Chilcott Manager Gets Probation For Fraud
• Fund Sues Theranos Over Stock Purchase Agreement
• Celladon Ditches Investor Suit Over Mydicar Trial Claims
• Sorin Can't Dodge Contaminated Hospital Equipment Suit
• St. Jude Warns Of Early Battery Depletion In Cardiac Devices
• E-Cig Makers Grilled On Challenge To FDA Rules
• Biotech Zymergen Banks $130M From Private Investors
• Highlights Of The FDA's Abbreviated New Drug Applications
• Mylan's EpiPen Rebate Errors Spark SEC Probe, Investor Suit
• Pfizer Wants Out Of Suit Over Pain Patch Marketing
• Patents For Computer Applications, Not Medical Diagnostics?
• 10 Things To Look For This Supreme Court Term
• Chancery Slashes Fee Request Fourfold In Cryo-Cell Case
• Taxation With Representation: Skadden, Latham, Kirkland
• Teva, Amneal Lose Opana ER Patent Fight Against Endo
• 23andMe Arbitration Order Refused Rehearing By 9th Circ.
• Mylan Inks $465M Deal Over EpiPen Rebates
• Don't Toss Meningitis MDL Cases On Technicality, Judge Told
• Roxane Asks Fed. Circ. To Halt Hetero's Generic Kidney Drug
• Sheller Spat Over FDA Risperdal Petition Denial Axed
• EPA, Chem Maker Settle Wash. Reservation Air Pollution Row
• Orange County DA Sues Over Niaspan Pay-For-Delay Scheme
• Nivea Skin-Firming Lotion An Unapproved Drug, Suit Says
• NY Health Dept. Wrongly Denying Speech Aids, Suit Says
• Kyle Bass Loses Challenge To Shire's Lialda Patent At PTAB
• Familes Blast GSK's New Zofran Label Submission In MDL
• J&J Attacks Cosmetics Expert In Baby Powder Cancer Trial
• DOJ Pummels Medical Supplier's Kickback Defenses
• FDA Issues New Rules For Pharmaceutical Patent Litigation
• Lamictal Pay-For-Delay Case Not Best High Court Lure
• ICU Medical Inks $1B Deal For Pfizer Infusion Therapy Unit
• Pfizer Wins Dismissal Of Zoloft Developmental Delay Suit
• McDermott Will Adds Silicon Valley M&A Partner From MoFo
• Coming Soon: The 3-D (And 4-D) Brief
• NJ Lawmakers Advance EpiPen Affordability Bill
• Fed. Circ. Judge Puzzled By USPTO Stance In Settled IP Row
• Health Care M&A Fades After Year In The Spotlight
• BTG Announces $36M Settlement Of DOJ Marketing Probe
• J&J Demands Mistrial As DePuy Chief Takes Stand
• Theranos Closing Labs, Slashing Staff Amid Legal Troubles
• J&J Should Have Warned Of Talc Risks Since 1982, Jury Told
• J&J Mea Culpa May Help Contain Device Data Security Fallout
• UnitedHealth Gouged Patients On Drug Prices, Suit Says
• Buyers Ask 1st Circ. For Nexium Antitrust Case Redo
• Parents Slam Bid To Toss GSK Zofran Suit From MDL
• FDA Must Block Virtus' Shoddy Meds, Drugmaker Says
• Minn. High Court Hears Medtronic Investor's Inversion Case
• Gov't EpiPen Spending Increased Nearly 500%, CMS Says
• Taxotere-Related Hair Loss Suits Centralized In Louisiana
• Pfizer Wields Ferring Win To Extend Combo Drug Exclusivity
• Teva Inks $769M Deal To Sell Allergan Assets In UK, Ireland
• Novartis Pays $35M To End Elidel Off-Label Marketing Suit
• 3rd Circ. Refuses To Revive Novartis Labeling Suit
• Worker's OT Class Claims Revived In Arbitration Dispute
• Boehringer Sheds US Pet Vaccines In $885M Elanco Deal
• Seyfarth Shaw Adds IP Boutique Fanelli Haag In DC
• 2nd Circ. Asked To Rethink Vitamin C Antitrust Class Action
• J&J Baby Powder Cancer MDL Centralized In NJ
• What To Expect From A Congressional Investigation
• US Asks High Court Not To Take Lamictal Pay-For-Delay Row
• The 'Tough Noogies' Doctrine: Rights But No Remedies
• Another Slam Dunk Infuse Win — Preemption and More
• Baxter Gets Medical Device Lawsuit Chopped In Half
• J&J Says Insulin Device Can Be Hacked But Risk Is Low
• TWi Awarded $12.7M In Bonds In Appetite Drug Patent Suit
• Aveeno Buyers Get Class Cert. In 'Natural' Labeling Suit
• J&J Attacks Alternative Artificial Hip During First Cross
• J&J Unit Challenges PTAB Institutions At High Court
• Procter & Gamble Renews Quick Win Bid In Fixodent MDL
• P&G Beats Old Spice Chemical Burn, Skin Rash Suit For Now
• J&J Hid Talc Baby Powder Cancer Risks, Jury Told
• FDA Warns That Hep C Meds Can Reactivate Hep B
• Pharmacists Duck Criminal Charges Over Meningitis Outbreak
• JPML Consolidates Abilify Gambling Suits In Florida
• Rainmaker Q&A: Deans & Lyons' Chad Castille
• Congress Clear About AIA's On-Sale Bar, Patent Office Says
• Enzo Hits Hologic With Suit Over DNA Patent
• Clarion Drops $311M On Mass. Life Sciences Complex
• Allergan Loses Bid For 3rd Circ. Rehearing Of Eye Drop Suit
• AdvoCare Wants To Arbitrate Ex-Director's Claim To CEO Spot
• FTC Warns Against Endo Privilege Request In Lidoderm MDL
• 3rd Circ. Confirms Free Assignability Of Antitrust Claims
• A Look At Manufacturer Liability For The Internet Of Things
• Bristol-Meyers May Slash Non-Californians From Ongylza Row
• J&J Artificial Hips' Market Success Built On Lies, Jury Told
• Customer Fights To Keep Sex Pill Suit From Being Rejected
• Boston Scientific Can't Escape $14.3M Mesh Defect Verdict
• Vitamin Maker Says 'Made In USA' Labeling Suit Is 'Cribbed'
• Justices Won't Eye Reach Of Hatch-Waxman Safe Harbor
• No End To IPO Flurry As 4 More Firms Reveal Plans
• 1st Circ. Won't Revive Suit Over Vertex Stock Drop
• Feds Say Shkreli, Ex-Atty Have Enough Info On Fraud Case
• High Court Won't Hear RICO Causation Suit Over Sanofi Drug
• Deals Rumor Mill: Royal Philips, Bai Brands, Concordia
• Justices Won't Hear Ruling That Mayo Dooms Genetic Patent
• Puma Investors' Suit Lives As Judge Dings Judicial Notice
• 3rd Circ. Denies Rehearing Of Claims-Aggregation Ruling
• Drug Cos. Deride FTC's Lidoderm, Opana Antitrust Suit
• Justices Reject Bias Dispute Over Arbitrator's BigLaw Brother
• Justices Won't Review FCA Disclosure, Pleading Concerns
• Private Investors Plug $95M Into New European Oncology Firm
• Aegerion Investor Says CEO Job Offer 'Taints' $43M Deal
• Texas Firm Will Pay $350K To Exit Fee Row Over Bayer MDL
• PE-Backed Medical Tech Firm Seeks $1.8B In London IPO
• Rainmaker Q&A: Nixon Peabody's Jill Gordon